POSTER SESSION A
Wednesday, June 20
5:30 p.m.-7:30 p.m.
Soprano Foyer

A01 The role of the tumor microenvironment in breast cancer dormancy. Andrea Walens. Duke University, Durham, NC.

A02 Quest for the Achilles' heel of residual disease in breast cancer. Ashna Alladin. European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.

A03 Understanding immunosuppressive mechanisms in metastatic mammary tumors. Denada Dibra. University of Texas MD Anderson Cancer Center, Houston, TX.

A04 PD-L1 and DNA mismatch repair protein PMS2 expression is triggered by aspirin plus FOLFOX chemotherapy in colon cancer cells induced in rats. Mohammed Faruk. Ahmadu Bello University, Zaria, Kaduna State, Nigeria.

A05 The role of MDSC cells in breast cancer dormancy and recurrence. Mahnaz Janghorban. Baylor College of Medicine, Houston, TX.

A06 Defining the heritable host TME modifiers that influence breast cancer dormancy and evolution. Michael Flister. Medical College of Wisconsin, Milwaukee, WI.


A08 Single-cell RNA sequencing in matched primary-lung metastasis triple-negative breast cancer patient-derived xenografts as a tool to map and isolate cellular populations enriched for metastatic genes. Constanza Martínez-Ramírez. Department of Pathology, McGill University and Rosalind & Morris Goodman Cancer Research Centre, Montreal, QC, Canada.


A10 Analysis of tissue-resident macrophages and their potential role in regulating disseminated tumor cell fate. Erica Dalla. Icahn School of Medicine at Mount Sinai, New York, NY.

A11 Disseminated tumor cells (DTC) of neuroblastoma patients undergo transcriptional alterations during disease progression—RNA-seq and first steps towards DTC-derived zebrafish xenografts. Fikret Rifatbegovic. Children's Cancer Research Institute, Vienna, Austria.
A12 Humanized mouse models for bone metastasis research: A bone ultrastructural analysis. Ines Moreno-Jimenez. Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.

A13 CXCL5 is a master regulator of the dormancy switch that activates proliferation of dormant breast cancer cells during bone metastasis. Laurie Littlepage. University of Notre Dame, Notre Dame, IN.

A14 NR2-SEMA3s-PLXNs axis regulates the dormancy state of disseminated tumor cells and metastasis progression in breast and head and neck cancer. Leire Recalde-Percaz. University of Barcelona, Barcelona, Spain.

A15 Laminin γ2 promotes breast cancer angiogenesis and lung colonization. Lena Wullkopf. Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark.

A16 Interleukin-6 trans-signaling regulates stemness of mammary epithelial cells but is physiologically disabled in disseminated breast cancer cells by bone marrow stromal cells. Melanie Werner-Klein. University of Regensburg, Regensburg, Germany.

A17 Roles of platelet-induced gene expression changes in metastatic niches. Myriam Labelle. St. Jude Children's Research Hospital, Memphis, TN.

A18 Palbociclib-resistant breast cancer cells are sensitized to inhibition of DNA repair and cancer stem cell pathways. Nicole Kettner. University of Texas MD Anderson Cancer Center, Houston, TX.

A19 Substance P and its receptor NK1 regulate disseminated tumor cells biology and dormancy. Paloma Bragado. IDIBAPS, Barcelona, Spain.

A20 PI3K—Therapeutic target in the metastatic microenvironment during early colonization? Raquel Blazquez. Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

A21 Estrogen promotes immune evasion in the liver to enhance metastatic expansion. Simon Milette. McGill University, Montreal, QC, Canada.

A22 Metastatic latency: Models and mechanisms. Srinivas Malladi. UT Southwestern Medical Center, Dallas, TX.

A23 The adhesion-linked proteins focal adhesion kinase and kindlin-1 control pulmonary metastatic colonization. Valerie Brunton. University of Edinburgh, Edinburgh, UK.

A24 LRRC15 is a novel promoter of ovarian cancer metastatic dissemination. Viji Shridhar. Mayo Clinic College of Medicine, Rochester, MN.

A25 NK cells govern breast cancer latency in the liver. Ana Luisa Correia. Department of Biomedicine, University of Basel/University Hospital Basel, Basel, Switzerland.

A26 Functional analysis of bone marrow niches driving disseminated cancer cell dormancy. Ana Rita Nobre. Icahn School of Medicine at Mount Sinai, New York, NY.
A27  Lymph node endothelia support disseminated tumor cell quiescence in vivo and in coculture models of tumor dormancy. Andrea Lim. University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA.


A29  Metabolic adaptations during tumor dormancy and recurrence. Douglas Fox. Duke University, Durham, NC.

A30  Analysis of dormancy mechanisms in uveal melanoma metastasis models. Eduardo Farias. Icahn School of Medicine at Mount Sinai, New York, NY.


A32  Osteoblasts are educated by disseminated breast cancer cells to mediate breast cancer cell proliferation in the bone microenvironment. Karen Bussard. Thomas Jefferson University, Philadelphia, PA.

A33  Melanoma dormancy and the aged tumor microenvironment: WNT5A drives disseminated melanoma cell dormancy. Mitchell Fane. Wistar Institute, Philadelphia, PA.

A34  DREAM as a novel regulator of ovarian cancer cell dormancy. Pirunthan Perampalam. Western University, London, ON, Canada.

A35  Versatile hydrogel platform to investigate dormancy in breast cancer bone metastasis. Sadra Bakhshandeh. Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.

A36  Biomaterial platform for evaluation of the link between dormancy and chemoresistance in ovarian cancer. Samira Azarin. University of Minnesota, Minneapolis, MN.

A38  Liver kinase B1 is required for ovarian cancer cell survival in models of tumor dormancy and metastasis. Trevor Shepherd. Western University, London, ON, Canada.


A40  Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in metastatic triple-negative breast cancer. Aurélie Cazet. The Kinghorn Cancer Center and Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

A41  Visualizing tumor dormancy in mouse models of cancer. Joshua Snyder. 1Duke University School of Medicine, Durham, NC.

A42  Regulation of breast cancer stem cell dormancy in the metastatic niche. Angélica Santiago-Gómez. Manchester Cancer Research Centre, University of Manchester, Manchester, United Kingdom.

A44  Isolation and analysis of bone marrow disseminated tumor cells from patients with localized prostate cancer. Frank Cackowski. University of Michigan, Ann Arbor, MI.

A45  Implantable humanized niches capture microenvironmental regulation of dormant disseminated human tumor cells. Ryan Carpenter. University of Massachusetts Amherst, Amherst, MA.